Celltrion Acquires France's 114-Year-Old Gifrer to Tap 9,000-Pharmacy Network

TL;DR - Celltrion bought 100% of French healthcare firm Gifrer to plug its denosumab biosimilars into France's pharmacy-substitution channel. - Gifrer brings 9,000+ pharmacies, 800 hospitals, and a 42% share in France's saline market; Celltrion guides ₩250 billion ($182 million) in incremental sales over five years. - Watch France's expected 2026 denosumab substitution ruling and any move by Celltrion to replicate the playbook in Germany.

Lead

Celltrion (068270.KS), Korea's largest biosimilar maker, said on May 12 it has acquired 100% of Gifrer, a 1912-founded French over-the-counter (OTC) and pharmacy products company, through its French subsidiary. The deal price was not disclosed by mutual agreement, but the strategic logic is explicit: Celltrion is buying a distribution channel rather than a drug, plugging its newly launched denosumab biosimilars into a French pharmacy network that biologics rarely reach. The transaction is expected to close after administrative procedures wrap by the end of May 2026.

What Happened

In a same-day disclosure carried by Yonhap News Agency, Hankyung, Chosun Biz and Maeil Business Newspaper, Celltrion said its French entity took a 100% stake in Gifrer (Gifrer Barbezat), a Lyon-region healthcare firm founded in 1912. According to Chosun Biz's reporting, Gifrer supplies more than 9,000 pharmacies and roughly 800 hospitals in France, carries a portfolio of about 140 OTC items, drugstore medicines and nutraceuticals — saline solution, teeth-whitening products and infant-care lines — and will keep its roughly 70 employees under full employment succession. Celltrion plans to run Gifrer as an independent subsidiary to preserve the local brand. Celltrion told reporters it expects the acquisition to generate about ₩250 billion ($182 million) in additional revenue over the next five years through the combined platform, per Chosun Biz.

Why It Matters

This is the first concrete signal that Celltrion is pivoting from a wholesale-distribution model in Europe to owning the last mile of the pharmacy shelf. The company's existing European footprint has been built on hospital tenders and partner distribution; until today it had no captive French retail-pharmacy presence. By bolting a 9,000-pharmacy network onto its biosimilar pipeline, Celltrion is positioning for a structural shift in how biologics reach French patients — pharmacy-level substitution rather than physician-led switching. The thesis the deal pressure-tests: that Korea's biosimilar majors can move up the European value chain by acquiring small, century-old local players, a template that has so far been used mainly by U.S. and European generics groups.

Business Impact

The near-term commercial driver, per Chosun Biz, is denosumab. France introduced pharmacy-level biosimilar substitution in 2022, expanded it to adalimumab (the molecule behind AbbVie's Humira) last year, and Celltrion expects denosumab — the molecule behind Amgen's Prolia and Xgeva — to be added in 2026. Celltrion's denosumab biosimilars Stoboclo and Osenvelt were approved by the U.S. FDA on March 3, 2025, with the FDA later granting interchangeability designation effective October 29, 2025; the products are also authorized in Europe. Pharmaceutical Executive and AJMC have both reported the FDA approvals, and Pharmacy Times reported the interchangeability designation. If France greenlights denosumab substitution as expected, Gifrer's pharmacy relationships become a direct channel rather than a wholesale handoff.

Gifrer also brings stand-alone OTC scale. According to Chosun Biz, Gifrer holds a 42% share of France's saline-solution market, ranking first, and a 28% share in teeth-whitening — two consumer-health categories that sit outside Celltrion's traditional biologic business. The Korea Herald and KED Global reported in February 2026 that Celltrion posted a record ₩4.16 trillion ($3.04 billion) in 2025 revenue and guided to ₩5.3 trillion ($3.87 billion) for 2026; the ₩250 billion five-year Gifrer contribution is modest against that base but reframes Celltrion's European mix toward retail.

Industry & Historical Context

France's biosimilar-substitution regime is one of Europe's most aggressive. As Hospital Pharmacy Europe has documented, pharmacist-level substitution of biologics — long resisted across the EU — was rolled out in France starting 2022, breaking with the hospital-dominant pattern in which, by earlier estimates, more than 40% of French biologic prescriptions were filled in hospitals. Adding adalimumab to the substitution list was a watershed because Humira was for years the world's best-selling drug; extending the policy to denosumab would widen the addressable retail-pharmacy market further.

Gifrer itself is one of the oldest names on French pharmacy shelves. Public brand histories trace its origin to a 1912 collaboration between chemist Paul-Louis Barbezat and the Gignoux brothers, and credit Gifrer with launching single-dose sterile physiological saline in 1981 — a format that became standard in French infant care. Acquiring a 114-year-old local brand is unusual for a Korean biopharma; Celltrion told reporters it intends to use Gifrer as a template for further M&A in Western and Eastern Europe where substitution policies are creating openings in retail pharmacy.

What to Watch

• French denosumab substitution decision (2026). Celltrion's stated case for the deal rests on France adding denosumab to its substitution list this year, per Chosun Biz. A delay or carve-out would push the payoff into 2027.
• Stoboclo and Osenvelt French uptake. With FDA interchangeability granted effective October 29, 2025 (Pharmacy Times) and EU authorization in hand, France will be the cleanest test of whether Celltrion can convert pharmacy access into share against Amgen's Prolia/Xgeva.
• Next European bolt-on. Celltrion told reporters it is reviewing similar local-pharmacy acquisitions in Germany and elsewhere; the next announcement will indicate whether Gifrer was opportunistic or the start of a series.
• OTC cross-sell. Whether Celltrion can push Gifrer's saline and teeth-whitening lines beyond France via its existing direct-sales infrastructure will determine if the ₩250 billion five-year revenue guide proves conservative.

Sources: - Yonhap News Agency — https://www.yna.co.kr/view/AKR20260512019400017 - Hankyung — https://www.hankyung.com/article/202605129626i - Chosun Biz — https://biz.chosun.com/science-chosun/bio/2026/05/12/5CQJMAN4Z5BPBJOALIJX6GH5OQ/ - Maeil Business Newspaper — https://www.mk.co.kr/news/it/12044248 - E-Today — https://www.etoday.co.kr/news/view/2583477 - Pharmaceutical Executive (FDA approval of Stoboclo/Osenvelt) — https://www.pharmexec.com/view/fda-approves-celltrion-biosimilars-stoboclo-osenvelt - AJMC (FDA approval of denosumab biosimilars) — https://www.ajmc.com/view/fda-approves-denosumab-biosimilars-stoboclo-and-osenvelt - Pharmacy Times (FDA interchangeability designation) — https://www.pharmacytimes.com/view/fda-grants-interchangeability-designation-to-denosumab-biosimilars-stoboclo-and-osenvelt - Korea Herald (Celltrion 2025 record earnings) — https://www.koreaherald.com/article/10670464 - KED Global (Celltrion 2026 guidance) — https://www.kedglobal.com/earnings/newsView/ked202602050006 - Hospital Pharmacy Europe (France substitution progress) — https://hospitalpharmacyeurope.com/news/france-biosimilar-substitution-plan-progresses/

By LineVest Markets Desk — May 12, 2026

This article is for informational purposes only and does not constitute investment advice.